T1	Participants 460 590	patients who had diabetes and had already been treated with angiotensin II receptor blockers and with or without thiazolidinedione
T2	Participants 652 807	Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40)
